Cogent Biosciences Inc.
Organization details
- Legal name
- Cogent Biosciences Inc.
- Former names
- Unum Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- COGT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001622229
- EIN
- 46-5308248
Board of directors
-
Andrew R. Robbins · Director · President and CEOSince 2023
-
Arlene Morris · DirectorSince 2023
-
Christopher W. Cain · DirectorSince 2023
-
Karen Jean Ferrante · DirectorSince 2023
-
Matthew Ros · DirectorSince 2023
- Since 2023
-
Todd Shegog · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
83.9%
-
86.7%
-
86.9%
Board connections
4 of this board's directors also sit on 12 other boards. 12 are in the same sector.
-
Viridian Therapeutics Inc. Same sectorvia Arlene Morris, Christopher W. Cain and Peter Evan Harwin
-
Damora Therapeutics Inc. Same sectorvia Christopher W. Cain and Peter Evan Harwin
-
Jade Biosciences Inc. Same sectorvia Christopher W. Cain and Peter Evan Harwin
-
Crescent Biopharma Inc. Same sectorvia Peter Evan Harwin
-
Dianthus Therapeutics Inc. Same sectorvia Peter Evan Harwin
-
Edgewise Therapeutics Inc. Same sectorvia Arlene Morris
-
Korsana Biosciences Inc. Same sectorvia Peter Evan Harwin
-
MacroGenics Inc. Same sectorvia Karen Jean Ferrante
-
Oruka Therapeutics Inc. Same sectorvia Peter Evan Harwin
-
Palatin Technologies Inc. Same sectorvia Arlene Morris
-
Spyre Therapeutics Inc. Same sectorvia Peter Evan Harwin
-
Zenas BioPharma Inc. Same sectorvia Peter Evan Harwin
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $383,888,094
- 8 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 27, 2026 | Arlene Morris Director | Option exercise | +41,927 | $5.64 | $236,468 |
| Aug 27, 2026 | Arlene Morris Director | Option exercise | +3,583 | $2.52 | $9,029 |
| Aug 27, 2026 | Arlene Morris Director | Open-market sale | −42,349 | $37.09 | $1,570,724 |
| Aug 27, 2026 | Arlene Morris Director | Open-market sale | −3,161 | $37.54 | $118,664 |
| May 19, 2026 | Andrew R. Robbins Director, Officer (President and CEO) | Gift | −160,000 | — | — |
| May 19, 2026 | Andrew R. Robbins Director, Officer (President and CEO) | Gift | +160,000 | — | — |
| Mar 31, 2026 | Fairmount Funds Management LLC Director | Derivative conversion | +7,000,000 | — | — |
| Mar 31, 2026 | Fairmount Funds Management LLC Director | Open-market sale | −7,000,000 | $34.66 | $242,620,000 |
| Jan 22, 2026 | Fairmount Funds Management LLC Director | Open-market sale | −3,500,000 | $36.40 | $127,400,000 |
| Dec 26, 2025 | Kearns Evan Officer (Chief Legal Officer) | Open-market sale | −65,000 | $38.70 | $2,515,500 |
| Dec 26, 2025 | Green John L. Officer (Chief Financial Officer) | Open-market sale | −77,000 | $38.68 | $2,978,360 |
| Dec 26, 2025 | Sachs Jessica Officer (Chief Medical Officer) | Open-market sale | −82,642 | $38.70 | $3,198,245 |
| Dec 26, 2025 | Robinson John Edward Officer (Chief Scientific Officer) | Open-market sale | −90,000 | $38.74 | $3,486,600 |
| Dec 17, 2025 | Robinson John Edward Officer (Chief Scientific Officer) | Grant or award | +50,000 | — | — |
| Dec 17, 2025 | Andrew R. Robbins Director, Officer (President and CEO) | Grant or award | +185,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Cogent Biosciences Inc.
Who is the CEO of Cogent Biosciences Inc.?
Andrew R. Robbins is Cogent Biosciences Inc.'s President and CEO.
How many directors are on Cogent Biosciences Inc.'s board?
Cogent Biosciences Inc.'s board has 7 directors: Andrew R. Robbins, Arlene Morris, Christopher W. Cain, Karen Jean Ferrante, Matthew Ros, Peter Evan Harwin and Todd Shegog.
Are Cogent Biosciences Inc. insiders buying or selling shares?
Over the last 12 months, Cogent Biosciences Inc. insiders made no open-market purchases and sold $383.9 million of shares in 8 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="cogent-biosciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.